Akebia Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-20.51	-5.35	-69.41	-51.93	-94.23	-282.02
Depreciation & Amortization	1.28	1.27	37.5	37.63	37.7	37.97
Stock-Based Compensation	12.76	11.28	7.78	9.32	17.85	22.74
Other Adjustments	32.29	44.31	23.15	2.32	-33.03	73.97
Change in Receivables	-1.97	-14.14	4.05	0.99	11.3	-24.03
Changes in Inventories	-20.71	-23.13	-28.4	-2.54	19.09	-24.95
Changes in Accounts Payable	-2.48	3.08	-1.36	-5.24	1.5	-11.74
Changes in Accrued Expenses	47.79	48.53	-12.78	-10.02	-38.01	-22.08
Changes in Unearned Revenue	3.26	2.68	-	-3.74	4.65	1.82
Changes in Other Operating Activities	-4.23	-0.55	-1.18	-0.18	0.02	-24.64
Operating Cash Flow	60.37	67.99	-40.66	-23.38	-73.15	-252.97
Capital Expenditures	-0.34	-0.29	-0.03	-	-0.11	-0.06
Sale of Property, Plant & Equipment	-	0.17	-	-	-	-
Purchases of Intangible Assets	-	-7.81	-	-	-	-
Proceeds from Sale of Investments	-	-	-	-	-	40
Investing Cash Flow	-8.14	-7.93	-0.03	-	-0.11	39.94
Long-Term Debt Issued	-	10	45	-	-	-
Long-Term Debt Repaid	-	-1.61	-37.1	-32	-33	-
Net Long-Term Debt Issued (Repaid)	-	8.39	7.9	-32	-33	-
Issuance of Common Stock	3.05	68.36	43.03	6.79	7.6	88.95
Net Common Stock Issued (Repurchased)	3.05	68.36	43.03	6.79	7.6	88.95
Other Financing Activities	-	-3.83	-1.27	-	40	44.78
Financing Cash Flow	-2.94	72.93	49.66	-25.21	14.6	133.73
Net Cash Flow	49.29	132.99	8.97	-48.59	-58.67	-79.29
Free Cash Flow	60.04	67.7	-40.69	-23.38	-73.27	-253.02
Free Cash Flow Growth	-11.32%	-	-	-	-	-
FCF Margin	25.83%	28.66%	-25.40%	-12.02%	-25.05%	-119.55%
Free Cash Flow Per Share	0.22	0.26	-0.19	-0.12	-0.40	-1.52
Levered Free Cash Flow	16.31	34.64	-67.76	-68.02	-102.38	-325.7
Unlevered Free Cash Flow	29.87	65.35	-56.72	-30.35	-55.94	-308.18

SEC Filings: 10-K · 10-Q